Copyright
©The Author(s) 2022.
World J Clin Oncol. Aug 24, 2022; 13(8): 688-701
Published online Aug 24, 2022. doi: 10.5306/wjco.v13.i8.688
Published online Aug 24, 2022. doi: 10.5306/wjco.v13.i8.688
Table 1 Comparison of pretransplant tumor characteristics, locoregional therapy, and posttransplant tumor characteristics between patients with intrahepatic cholangiocarcinoma and hepatocellular carcinoma, matched 1:8 for pre-liver transplant factors and explant factors
| Variable | Pre-LT factors | Explant factors | |||
| ICC (n = 8) | HCC (n = 64) | P value | HCC (n = 64) | P value | |
| Recipient characteristics | |||||
| Age, mean ± SD | 59.4 ± 7.6 | 61.5 ± 8.0 | 0.489 | 60.3 ± 8.6 | 0.7742 |
| Male, n (%) | 5 (62.5) | 44 (68.8) | 0.704 | 50 (78.1) | 0.3821 |
| Etiology of liver disease, n (%) | 0.201 | 0.7451 | |||
| HCV | 6 (75.0) | 50 (78.1) | 45 (70.3) | ||
| Alcohol | 0 | 9 (14.1) | 10 (15.6) | ||
| HBV | 0 | 1 (1.6) | 3 (4.7) | ||
| NAFLD | 1 (12.5) | 2 (3.1) | 1 (1.6) | ||
| Cryptogenic | 1 (12.5) | 1 (1.6) | 2 (3.1) | ||
| Other | 0 | 1 (1.6) | 3 (4.7) | ||
| CTP class, n (%) | 0.168 | 0.2101 | |||
| A | 7 (87.5) | 43 (67.2) | 40 (63.5) | ||
| B | 0 | 17 (26.6) | 19 (30.2) | ||
| C | 1 (12.5) | 4 (6.3) | 4 (6.3) | ||
| Maximum pretransplant AFP, ng/mL | 28.5 (1.60-801.0) | 10.8 (1.7-1133.0) | 0.324 | 12.5 (1.3-6123.0) | 0.6203 |
| Radiographic tumor characteristics | |||||
| Cumulative tumor diameter, cm, n (%) | 0.072 | 0.8621 | |||
| < 2.1 | 1 (12.5) | 21 (32.8) | 9 (14.1) | ||
| 2.2-5.0 | 4 (50.0) | 37 (57.8) | 39 (60.9) | ||
| > 5.1 | 3 (37.5) | 6 (9.4) | 16 (25.0) | ||
| Neoadjuvant therapy, n (%) | 0.036 | 0.0161 | |||
| None | 0 | 21 (32.8) | 21 (32.8) | ||
| TACE | 8 (100.0) | 32 (50.0) | 29 (45.3) | ||
| Other | 0 | 11 (17.2) | 14 (21.9) | ||
| Pathologic tumor characteristics, n (%) | |||||
| Total necrosis among treated patients, n/total n (%) | 1/8 (12.5) | 25/43 (58.1) | 0.008 | 7/43 (16.3) | 0.7411 |
| Within Milan criteria | 3 (37.5) | 52 (81.3) | 0.015 | 35 (54.7) | 0.4631 |
| Within UCSF criteria | 6 (75.0) | 56 (87.5) | 0.307 | 46 (71.9) | > 0.9991 |
| Median cumulative nodule size | 0.072 | 0.8621 | |||
| < 2.1 | 1 (12.5) | 21 (32.8) | 9 (14.1) | ||
| 2.2-5.0 | 4 (50.0) | 37 (57.8) | 39 (60.9) | ||
| > 5.1 | 3 (37.5) | 6 (9.4) | 16 (25.0) | ||
| Tumor grade, n/total n (%) | 0.225 | 0.2141 | |||
| 1 | 2 (25.0) | 28 (43.8) | 4 (6.3) | ||
| 2 | 4 (50.0) | 31 (48.4) | 40 (62.5) | ||
| 3 | 2 (25.0) | 5 (7.8) | 20 (31.3) | ||
| Microvascular invasion | 3 (37.5) | 6 (9.4) | 0.056 | 20 (31.3) | 0.7411 |
Table 2 Comparison of pretransplant tumor characteristics, locoregional therapy, and posttransplant tumor characteristics between patients with mixed hepatocellular-cholangiocarcinoma and hepatocellular carcinoma, matched 1:8 for pre- liver transplant factors and explant factors
| Variable | Pre-LT factors | Explant factors | |||
| HCC-CC (n = 7) | HCC (n = 56) | P value | HCC (n = 56) | P value | |
| Recipient characteristics | |||||
| Age, mean ± SD | 58.0 ± 6.9 | 60.3 ± 9.2 | 0.317 | 60.8 ± 7.1 | 0.2892 |
| Male, n (%) | 4 (57.1) | 41 (73.2) | 0.397 | 4 (57.1) | 0.3751 |
| Etiology of liver disease, n (%) | 0.192 | 0.7891 | |||
| HCV | 6 (85.7) | 42 (75.0) | 41 (73.2) | ||
| Alcohol | 0 | 7 (12.5) | 3 (5.4) | ||
| HBV | 0 | 5 (8.9) | 5 (8.9) | ||
| NAFLD | 1 (14.3) | 0 | 3 (5.4) | ||
| Cryptogenic | 0 | 2 (3.6) | 4 (7.1) | ||
| CTP class, n (%) | 0.201 | 0.5561 | |||
| A | 3 (42.9) | 21 (37.5) | 29 (51.8) | ||
| B | 2 (28.6) | 30 (53.6) | 20 (35.7) | ||
| C | 2 (28.6) | 5 (8.9) | 7 (12.5) | ||
| Maximum pretransplant AFP, ng/mL | 35.3(4.3-357.0) | 9.6(1.1-628.0) | 0.150 | 16.5(1.1-6123.0) | 0.6683 |
| Radiographic tumor characteristics | |||||
| Cumulative tumor diameter, cm, n (%) | 0.224 | 0.723t | |||
| < 2.1 | 1 (14.3) | 25 (44.6) | 11 (19.6) | ||
| 2.2-5.0 | 4 (57.1) | 23 (41.1) | 36 (64.3) | ||
| 5.1 | 2 (28.6) | 8 (14.3) | 9 (16.1) | ||
| Neoadjuvant therapy, n (%) | 0.085 | 0.0811 | |||
| None | 0 | 14 (25.0) | 12 (21.4) | ||
| TACE | 3 (42.9) | 22 (39.3) | 28 (50.0) | ||
| Other | 4 (57.1) | 20 (35.7) | 16 (28.6) | ||
| Pathologic tumor characteristics, n (%) | |||||
| Total necrosis among treated patients, n/total n (%) | 3/7 (33.3) | 20/42 (47.6) | 0.8000 | 18/44 (40.1) | 0.2231 |
| Within Milan criteria | 4 (57.1) | 39 (69.6) | 0.669 | 35 (62.5) | > 0.9991 |
| Within UCSF criteria | 6 (85.7) | 49 (87.5) | > 0.999 | 45 (80.4) | > 0.9991 |
| Median cumulative nodule size | 0.224 | 0.7231 | |||
| < 2.1 | 1 (14.3) | 25 (44.6) | 11 (19.6) | ||
| 2.2-5.0 | 4 (57.1) | 23 (41.1) | 36 (64.3) | ||
| > 5.1 | 2 (28.6) | 8 (14.3) | 9 (16.1) | ||
| Tumor grade, n/total n (%) | 0.722 | 0.2331 | |||
| 1 | 0 | 1/36 (2.8) | 0 | ||
| 2 | 4/7 (57.1) | 24/36 (66.7) | 18/55 (32.7) | ||
| 3 | 3/7 (42.9) | 11/36 (30.6) | 37/55 (67.3) | ||
| Microvascular invasion | 0 | 9 (16.1) | 0.580 | 0 | 0 |
- Citation: Brandão ABM, Rodriguez S, Fleck Jr AM, Marroni CA, Wagner MB, Hörbe A, Fernandes MV, Cerski CT, Coral GP. Propensity-matched analysis of patients with intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma and hepatocellular carcinoma undergoing a liver transplant. World J Clin Oncol 2022; 13(8): 688-701
- URL: https://www.wjgnet.com/2218-4333/full/v13/i8/688.htm
- DOI: https://dx.doi.org/10.5306/wjco.v13.i8.688